Publications by authors named "Kimihiko Takeuchi"
Article Synopsis
- - The study analyzed data from the ORIGAMI trial to determine if adding methotrexate (MTX) affects the outcomes of abatacept treatment in patients with rheumatoid arthritis who hadn't used biologics before.
- - A total of 325 patients were split into two groups: those who received abatacept alone (MTX-) and those who received it with MTX (MTX+), and various health indicators were assessed over 52 weeks.
- - Results showed no significant differences in disease activity or retention rates of abatacept between the two groups after a year, suggesting that using MTX alongside abatacept might not provide extra benefits.
To assess the middle-term outcome of iguratimod (IGU) in rheumatoid arthritis (RA) patients. Sixty-nine RA patients (14 males and 55 females, mean age of 64.0 years) receiving IGU-containing therapies were enrolled.
View Article and Find Full Text PDFBackground: Most people with rheumatoid arthritis (RA) are physically inactive. An accelerometer worn on the waist has been used to evaluate physical activity in people with chronic conditions. It is useful for evaluating moderate to vigorous activity, although it tends to underestimate light or mild activities such as housework or family duties.
View Article and Find Full Text PDFArticle Synopsis
- * A significant correlation was found between the FDG-PET standardized uptake value (SUV) and joint destruction progression, indicating that higher FDG uptake is linked to worse outcomes, both in weight-bearing and non-weight-bearing joints.
- * Factors influencing joint damage included a higher SUV and lower doses of prednisolone, suggesting that inflammation, indicated by FDG uptake, may predict future radiographic changes in RA patients.
Objective: The aim of this study was to compare the efficacy and safety of golimumab (GLM) 50 mg + methotrexate (MTX) combination therapy and GLM 100 mg monotherapy in patients with rheumatoid arthritis (RA).
Methods: The subjects were 115 RA patients (92 females and 23 males; median (range) age, 64 (17-87) years; median (range) disease duration, 8 (0.6-48) years) started on GLM.
The patient was a 77-year-old woman diagnosed as having rheumatoid arthritis (RA) in 1973. She was initiated on infliximab therapy in addition to methotrexate administration in 2009. The therapeutic response decreased after the fifth dose of infliximab, and the patient developed rheumatoid pleuritis due to increased RA disease activity.
View Article and Find Full Text PDFObjectives: To evaluate whether there is a correlation between the differences in joint uptake of 2-[18F]-fluoro-2-deoxy-d-glucose ((18)F-FDG) and the improvement of clinical findings in RA patients undergoing anti-TNF therapies.
Methods: Twenty-two patients who received anti-TNF therapies, including infliximab for 16 patients and etanercept for 6 patients, were assessed. PET with (18)F-FDG studies and clinical assessments were performed at baseline and 6 months after the initiation of therapy.
We report the case of a 50-year-old Japanese woman with SAPHO (synovitis-acne-pustulosis-hyperostosis-osteomyelitis) syndrome. Radiographs showed osteosclerosis of the cervical and lumbar vertebrae, as well as osteosclerosis and osteolysis of the right femoral neck, resembling multiple metastatic bony lesions. Arriving at a diagnosis required hematological and imaging tests.
View Article and Find Full Text PDFPurpose: The relative utility of various preoperative diagnostic imaging modalities for the evaluation of hemangioma of the extremities, including positron emission tomography (PET) (using 18F-fluoro-2-deoxy-D-glucose [FDG] and fluorine-18 alpha-methyltyrosine [FMT]), computed tomography (CT), magnetic resonance imaging (MRI), and digital subtraction angiography (DSA), was investigated.
Methods: Imaging findings in 16 patients with 16 histopathologically documented hemangiomas of the extremities were retrospectively reviewed. Preoperative imaging included: FDG-PET (n = 16), FMT-PET (n = 12), MRI (n =16), CT (n =11), and DSA (n =14).